Hereditary Transthyretin Amyloidosis (hATTR)

FDA Approves Record-Breaking 59 Novel Drugs in 2018

Approvals, Calcitonin Gene-Related Peptide (CGRP), Cancer, Dravet syndrome, Epilepsy, Fabry Disease, FDA, FDA/Regulatory, First-In-Class, Hereditary Transthyretin Amyloidosis (hATTR), Migraine, New Molecular Entities, Polyneuropathy, RNA Interference (RNAi), Seizures

Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.

January 15, 2019/by BioSpace

Akcea and Ionis Announce EU Approval of Tegsedi

European Commission, FDA/Regulatory, Hereditary Transthyretin Amyloidosis (hATTR), Neuropathy, RNAi therapeutics

Akcea and Ionis’ Tegsedi (inotersen) received marketing authorization approval from the European Commission for treating stage 1 or stage 2 polyneuropathy in adults with hATTR.

July 11, 2018/by GlobeNewswire